α-synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies

Nature Medicine

Volumn 23, Issue 2, 2017, Pages 1-13

  Wong, Yvette C ^a   Krainc, Dimitri ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN; PROTEIN AGGREGATE;

ACTIVE IMMUNIZATION; AGING; ALZHEIMER DISEASE; AUTOPHAGY; CELL FUNCTION; CELL MIGRATION; CELL ORGANELLE; DEGENERATIVE DISEASE; ENDOPLASMIC RETICULUM; ENDOSOME; GLIA; GOLGI COMPLEX; HUMAN; LYSOSOME; MITOCHONDRION; MOLECULAR DYNAMICS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW; SYNAPSE VESICLE; DIFFUSE LEWY BODY DISEASE; METABOLISM; MOLECULARLY TARGETED THERAPY; NERVE CELL; NERVE FIBER TRANSPORT; PARKINSON DISEASE; PROTEINOSIS; SHY DRAGER SYNDROME; SYNAPSE;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AUTOPHAGY; AXONAL TRANSPORT; ENDOPLASMIC RETICULUM; GOLGI APPARATUS; HUMANS; LEWY BODY DISEASE; LYSOSOMES; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; MULTIPLE SYSTEM ATROPHY; NEURONS; PARKINSON DISEASE; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; SYNAPSES; TAU PROTEINS;

EID: 85011818934     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4269     Document Type: Review

References (215)

1. Spillantini, M.G. et al. α-synuclein in Lewy bodies. Nature 388, 839-840 (1997).
2. Burré, J. et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663-1667 (2010).
3. Bendor, J.T., Logan, T.P. & Edwards, R.H. The function of α-synuclein. Neuron 79, 1044-1066 (2013).
4. Polymeropoulos, M.H. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
5. Krüger, R. et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108 (1998).
6. Zarranz, J.J. et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173 (2004).
7. Appel-Cresswell, S. et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28, 811-813 (2013).
8. Proukakis, C. et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 80, 1062-1064 (2013).
9. Lesage, S. et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459-471 (2013).
10. Pasanen, P. et al. Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging 35, 2180e.1-2180.e5 (2014).
11. Singleton, A.B. et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).
12. Chartier-Harlin, M.C. et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169 (2004).
13. Simón-Sánchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312 (2009).
14. Nalls, M.A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46, 989-993 (2014).
15. Soldner, F. et al. Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression. Nature 533, 95-99 (2016).
16. Spillantini, M.G. et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208 (1998).
17. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M. & Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473 (1998).
18. Shachar, T. et al. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov. Disord. 26, 1593-1604 (2011).
19. Bachhuber, T. et al. Inhibition of amyloid-β plaque formation by α-synuclein. Nat. Med. 21, 802-807 (2015).
20. Guo, J.L. et al. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103-117 (2013).
21. Yoshimoto, M. et al. NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc. Natl. Acad. Sci. USA 92, 9141-9145 (1995).
22. Masliah, E. et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. USA 98, 12245-12250 (2001).
23. Giasson, B.I. et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636-640 (2003).
24. Kalia, L.V. & Lang, A.E. Parkinson's disease. Lancet 386, 896-912 (2015).
25. Frigerio, R. et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol. Aging 32, 857-863 (2011).
26. Paisán-Ruíz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600 (2004).
27. Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607 (2004).
28. Trinh, J., Guella, I. & Farrer, M.J. Disease penetrance of late-onset parkinsonism: a meta-analysis. JAMA Neurol. 71, 1535-1539 (2014).
29. Lin, X. et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64, 807-827 (2009).
30. Daher, J.P. et al. Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration. J. Biol. Chem. 290, 19433-19444 (2015).
31. Daher, J.P., Volpicelli-Daley, L.A., Blackburn, J.P., Moehle, M.S. & West, A.B. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc. Natl. Acad. Sci. USA 111, 9289-9294 (2014).
32. Volpicelli-Daley, L.A. et al. G2019S-LRRK2 expression augments α-synuclein sequestration into inclusions in neurons. J. Neurosci. 36, 7415-7427 (2016).
33. Fanciulli, A. & Wenning, G.K. Multiple-system atrophy. N. Engl. J. Med. 372, 249-263 (2015).
34. Goldman, J.G., Williams-Gray, C., Barker, R.A., Duda, J.E. & Galvin, J.E. The spectrum of cognitive impairment in Lewy body diseases. Mov. Disord. 29, 608-621 (2014).
35. Huang, Y. & Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222 (2012).
36. Larson, M.E. et al. Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J. Neurosci. 32, 10253-10266 (2012).
37. Blanz, J. & Saftig, P. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance. J. Neurochem. 139 (Suppl. 1), 198-215 (2016).
38. Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651-1661 (2009).
39. Arber, C.E., Li, A., Houlden, H. & Wray, S. Review: Insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories. Neuropathol. Appl. Neurobiol. 42, 220-241 (2016).
40. Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A. & Lansbury, P.T. Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715 (1996).
41. Iwai, A., Yoshimoto, M., Masliah, E. & Saitoh, T. Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 34, 10139-10145 (1995).
42. Rodriguez, J.A. et al. Structure of the toxic core of α-synuclein from invisible crystals. Nature 525, 486-490 (2015).
43. Iwai, A. et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475 (1995).
44. Kahle, P.J. et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373 (2000).
45. Davidson, W.S., Jonas, A., Clayton, D.F. & George, J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449 (1998).
46. Varkey, J. et al. Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J. Biol. Chem. 285, 32486-32493 (2010).
47. Chandra, S., Gallardo, G., Fernández-Chacón, R., Schlüter, O.M. & Südhof, T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123, 383-396 (2005).
48. Cabin, D.E. et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22, 8797-8807 (2002).
49. Murphy, D.D., Rueter, S.M., Trojanowski, J.Q. & Lee, V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-3220 (2000).
50. Scott, D. & Roy, S. α-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J. Neurosci. 32, 10129-10135 (2012).
51. Diao, J. et al. Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. eLife 2, e00592 (2013).
52. Vargas, K.J. et al. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J. Neurosci. 34, 9364-9376 (2014).
53. Choi, B.K. et al. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. USA 110, 4087-4092 (2013).
54. Wang, L. et al. α-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol. 24, 2319-2326 (2014).
55. Nemani, V.M. et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66-79 (2010).
56. Burré, J., Sharma, M. & Südhof, T.C. α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl. Acad. Sci. USA 111, E4274-E4283 (2014).
57. Burré, J., Sharma, M. & Südhof, T.C. Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J. Neurosci. 32, 15227-15242 (2012).
58. Abeliovich, A. et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252 (2000).
59. Mosharov, E.V. et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62, 218-229 (2009).
60. Masliah, E. et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
61. Janezic, S. et al. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl. Acad. Sci. USA 110, E4016-E4025 (2013).
62. Lundblad, M., Decressac, M., Mattsson, B. & Björklund, A. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. USA 109, 3213-3219 (2012).
63. Nunnari, J. & Suomalainen, A. Mitochondria: in sickness and in health. Cell 148, 1145-1159 (2012).
64. Martin, L.J. et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41-50 (2006).
65. Choubey, V. et al. Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J. Biol. Chem. 286, 10814-10824 (2011).
66. Chen, L., Xie, Z., Turkson, S. & Zhuang, X. A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. J. Neurosci. 35, 890-905 (2015).
67. Kamp, F. et al. Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 29, 3571-3589 (2010).
68. Nakamura, K. et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 286, 20710-20726 (2011).
69. Dauer, W. et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 99, 14524-14529 (2002).
70. Luth, E.S., Stavrovskaya, I.G., Bartels, T., Kristal, B.S. & Selkoe, D.J. Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J. Biol. Chem. 289, 21490-21507 (2014).
71. Di Maio, R. et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Sci. Transl. Med. 8, 342ra78 (2016).
72. Eschbach, J. et al. Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann. Neurol. 77, 15-32 (2015).
73. Zheng, B. et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2, 52ra73 (2010).
74. Ryan, S.D. et al. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell 155, 1351-1364 (2013).
75. Outeiro, T.F. & Lindquist, S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 1772-1775 (2003).
76. Cooper, A.A. et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324-328 (2006).
77. Gitler, A.D. et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. USA 105, 145-150 (2008).
78. Chung, C.Y. et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 342, 983-987 (2013).
79. Tardiff, D.F. et al. Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science 342, 979-983 (2013).
80. Mazzulli, J.R. et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52 (2011).
81. Mazzulli, J.R., Zunke, F., Isacson, O., Studer, L. & Krainc, D. α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc. Natl. Acad. Sci. USA 113, 1931-1936 (2016).
82. Thayanidhi, N. et al. Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol. Biol. Cell 21, 1850-1863 (2010).
83. Oaks, A.W., Marsh-Armstrong, N., Jones, J.M., Credle, J.J. & Sidhu, A. Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. PLoS One 8, e70872 (2013).
84. Caraveo, G. et al. Calcineurin determines toxic versus beneficial responses to α-synuclein. Proc. Natl. Acad. Sci. USA 111, E3544-E3552 (2014).
85. Luo, J. et al. A calcineurin-and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons. Hum. Mol. Genet. 23, 6567-6574 (2014).
86. Bellucci, A. et al. Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. J. Neurochem. 116, 588-605 (2011).
87. Colla, E. et al. Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J. Neurosci. 32, 3306-3320 (2012).
88. Colla, E. et al. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J. Neurosci. 32, 3301-3305 (2012).
89. Wong, Y.C. & Holzbaur, E.L. Autophagosome dynamics in neurodegeneration at a glance. J. Cell Sci. 128, 1259-1267 (2015).
90. Winslow, A.R. et al. α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol. 190, 1023-1037 (2010).
91. Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T. & Sulzer, D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295 (2004).
92. Martinez-Vicente, M. et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118, 777-788 (2008).
93. Tanik, S.A., Schultheiss, C.E., Volpicelli-Daley, L.A., Brunden, K.R. & Lee, V.M. Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy. J. Biol. Chem. 288, 15194-15210 (2013).
94. Volpicelli-Daley, L.A. et al. Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. Mol. Biol. Cell 25, 4010-4023 (2014).
95. Wong, Y.C. & Krainc, D. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease. Mov. Disord. 31, 1610-1618 (2016).
96. Maroteaux, L., Campanelli, J.T. & Scheller, R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815 (1988).
97. Rousseaux, M.W. et al. TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. eLife 5, e19809 (2016).
98. Kontopoulos, E., Parvin, J.D. & Feany, M.B. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15, 3012-3023 (2006).
99. Fares, M.B. et al. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum. Mol. Genet. 23, 4491-4509 (2014).
100. Decressac, M. et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl. Acad. Sci. USA 110, E1817-E1826 (2013).
101. Phillips, M.J. & Voeltz, G.K. Structure and function of ER membrane contact sites with other organelles. Nat. Rev. Mol. Cell Biol. 17, 69-82 (2016).
102. Calì, T., Ottolini, D., Negro, A. & Brini, M. α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 287, 17914-17929 (2012).
103. Guardia-Laguarta, C. et al. α-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci. 34, 249-259 (2014).
104. Chu, Y. et al. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 135, 2058-2073 (2012).
105. Prots, I. et al. α-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J. Biol. Chem. 288, 21742-21754 (2013).
106. Tilve, S., Difato, F. & Chieregatti, E. Cofilin 1 activation prevents the defects in axon elongation and guidance induced by extracellular alpha-synuclein. Sci. Rep. 5, 16524 (2015).
107. Mazzulli, J.R. et al. Activation of β-glucocerebrosidase reduces pathological α-synuclein and restores lysosomal function in Parkinson's patient midbrain neurons. J. Neurosci. 36, 7693-7706 (2016).
108. Bousset, L. et al. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 4, 2575 (2013).
109. Auluck, P.K., Chan, H.Y., Trojanowski, J.Q., Lee, V.M. & Bonini, N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868 (2002).
110. Ihara, M. et al. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 53, 519-533 (2007).
111. Outeiro, T.F. et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519 (2007).
112. Chen, L. & Feany, M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8, 657-663 (2005).
113. Bender, A. et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515-517 (2006).
114. Vilchez, D., Saez, I. & Dillin, A. The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat. Commun. 5, 5659 (2014).
115. Li, W. et al. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J. Neurosci. 24, 7400-7409 (2004).
116. Chu, Y. & Kordower, J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol. Dis. 25, 134-149 (2007).
117. Finkel, T. & Holbrook, N.J. Oxidants, oxidative stress and the biology of ageing. Nature 408, 239-247 (2000).
118. Giasson, B.I. et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985-989 (2000).
119. Paxinou, E. et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 8053-8061 (2001).
120. Hodara, R. et al. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem. 279, 47746-47753 (2004).
121. Zecca, L. et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J. Neurochem. 106, 1866-1875 (2008).
122. Halliday, G.M., Macdonald, V. & Henderson, J.M. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain 128, 2272-2280 (2005).
123. Sulzer, D. & Surmeier, D.J. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov. Disord. 28, 41-50 (2013).
124. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
125. Conway, K.A., Rochet, J.C., Bieganski, R.M. & Lansbury, P.T. Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349 (2001).
126. Mazzulli, J.R., Armakola, M., Dumoulin, M., Parastatidis, I. & Ischiropoulos, H. Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J. Biol. Chem. 282, 31621-31630 (2007).
127. Mazzulli, J.R. et al. Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26, 10068-10078 (2006).
128. Hirsch, E., Graybiel, A.M. & Agid, Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348 (1988).
129. Chakrabarty, P. et al. Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcification. Nat. Neurosci. 14, 694-696 (2011).
130. Yazawa, I. et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45, 847-859 (2005).
131. Lindersson, E. et al. p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J. Biol. Chem. 280, 5703-5715 (2005).
132. Ubhi, K. et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J. Neurosci. 30, 6236-6246 (2010).
133. Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B. & Olanow, C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504-506 (2008).
134. Li, J.Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501-503 (2008).
135. Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. USA 106, 13010-13015 (2009).
136. Luk, K.C. et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA 106, 20051-20056 (2009).
137. Volpicelli-Daley, L.A. et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57-71 (2011).
138. Luk, K.C. et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012).
139. Sacino, A.N. et al. Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. USA 111, 10732-10737 (2014).
140. Peelaerts, W. et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340-344 (2015).
141. Rey, N.L. et al. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J. Exp. Med. 213, 1759-1778 (2016).
142. Danzer, K.M. et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7, 42 (2012).
143. Tsunemi, T., Hamada, K. & Krainc, D. ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein. J. Neurosci. 34, 15281-15287 (2014).
144. Kong, S.M. et al. Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes. Hum. Mol. Genet. 23, 2816-2833 (2014).
145. Chutna, O. et al. The small GTPase Rab11 co-localizes with α-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity. Hum. Mol. Genet. 23, 6732-6745 (2014).
146. Emmanouilidou, E. et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838-6851 (2010).
147. Oh, S.H. et al. Mesenchymal stem cells inhibit transmission of α-Synuclein by modulating clathrin-mediated endocytosis in a Parkinsonian model. Cell Rep. 14, 835-849 (2016).
148. Mao, X. et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374 (2016).
149. Abounit, S. et al. Tunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes. EMBO J. 35, 2120-2138 (2016).
150. Brettschneider, J., Del Tredici, K., Lee, V.M. & Trojanowski, J.Q. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat. Rev. Neurosci. 16, 109-120 (2015).
151. Walsh, D.M. & Selkoe, D.J. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat. Rev. Neurosci. 17, 251-260 (2016).
152. Lee, H.J. et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285, 9262-9272 (2010).
153. Ouchi, Y. et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57, 168-175 (2005).
154. Stefanova, N. et al. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov. Disord. 22, 2196-2203 (2007).
155. Chung, C.Y., Koprich, J.B., Siddiqi, H. & Isacson, O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 29, 3365-3373 (2009).
156. Theodore, S., Cao, S., McLean, P.J. & Standaert, D.G. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 67, 1149-1158 (2008).
157. Lastres-Becker, I. et al. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum. Mol. Genet. 21, 3173-3192 (2012).
158. Gao, H.M. et al. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28, 7687-7698 (2008).
159. Harms, A.S. et al. MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J. Neurosci. 33, 9592-9600 (2013).
160. Kim, C. et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562 (2013).
161. Daniele, S.G. et al. Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders. Sci. Signal. 8, ra45 (2015).
162. Wang, S. et al. α-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation. Proc. Natl. Acad. Sci. USA 112, E1926-E1935 (2015).
163. Thome, A.D., Harms, A.S., Volpicelli-Daley, L.A. & Standaert, D.G. microRNA-155 regulates alpha-synuclein-induced inflammatory responses in models of Parkinson disease. J. Neurosci. 36, 2383-2390 (2016).
164. Ejlerskov, P. et al. Lack of neuronal IFN-β-IFNAR causes Lewy body-and Parkinson's disease-like dementia. Cell 163, 324-339 (2015).
165. Hamza, T.H. et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 42, 781-785 (2010).
166. Roy, B. & Jackson, G.R. Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Hum. Mol. Genet. 23, 3008-3023 (2014).
167. Lewis, J. et al. In vivo silencing of alpha-synuclein using naked siRNA. Mol. Neurodegener. 3, 19 (2008).
168. Cooper, J.M. et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov. Disord. 29, 1476-1485 (2014).
169. Rott, R. et al. α-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proc. Natl. Acad. Sci. USA 108, 18666-18671 (2011).
170. Tofaris, G.K. et al. Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl. Acad. Sci. USA 108, 17004-17009 (2011).
171. Oueslati, A., Schneider, B.L., Aebischer, P. & Lashuel, H.A. Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl. Acad. Sci. USA 110, E3945-E3954 (2013).
172. McGlinchey, R.P. & Lee, J.C. Cysteine cathepsins are essential in lysosomal degradation of α-synuclein. Proc. Natl. Acad. Sci. USA 112, 9322-9327 (2015).
173. Masliah, E. et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6, e19338 (2011).
174. Bae, E.J. et al. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32, 13454-13469 (2012).
175. Sardi, S.P. et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl. Acad. Sci. USA 110, 3537-3542 (2013).
176. Rocha, E.M. et al. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Neurobiol. Dis. 82, 495-503 (2015).
177. Rockenstein, E. et al. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease. Hum. Mol. Genet. 25, 2645-2660 (2016).
178. Aflaki, E. et al. A new glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism. J. Neurosci. 36, 7441-7452 (2016).
179. Pchelina, S.N. et al. Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases. Neurosci. Lett. 583, 188-193 (2014).
180. Rothaug, M. et al. LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance. Proc. Natl. Acad. Sci. USA 111, 15573-15578 (2014).
181. Gitler, A.D. et al. α-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 41, 308-315 (2009).
182. Tsunemi, T. & Krainc, D. Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum. Mol. Genet. 23, 2791-2801 (2014).
183. Fonseca-Ornelas, L. et al. Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation. Nat. Commun. 5, 5857 (2014).
184. Lindström, V. et al. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice. Neurobiol. Dis. 69, 134-143 (2014).
185. Dettmer, U. et al. Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun. 6, 7314 (2015).
186. Schneeberger, A., Tierney, L. & Mandler, M. Active immunization therapies for Parkinson's disease and multiple system atrophy. Mov. Disord. 31, 214-224 (2016).
187. Games, D. et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J. Neurosci. 34, 9441-9454 (2014).
188. Tran, H.T. et al. A-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep. 7, 2054-2065 (2014).
189. Masliah, E. et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857-868 (2005).
190. Bergstrom, A.L., Kallunki, P. & Fog, K. Development of passive immunotherapies for synucleinopathies. Mov. Disord. 31, 203-213 (2016).
191. Beal, M.F. et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71, 543-552 (2014).
192. Sybertz, E. & Krainc, D. Development of targeted therapies for Parkinson's disease and related synucleinopathies. J. Lipid Res. 55, 1996-2003 (2014).
193. Chen-Plotkin, A.S. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron 84, 594-607 (2014).
194. Van der Perren, A. et al. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease. Neurobiol. Aging 36, 1559-1568 (2015).
195. Qin, H. et al. Inhibition of the JAK/STAT pathway protects against α-synuclein-induced neuroinflammation and dopaminergic neurodegeneration. J. Neurosci. 36, 5144-5159 (2016).
196. Valera, E., Mante, M., Anderson, S., Rockenstein, E. & Masliah, E. Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J. Neuroinflammation 12, 93 (2015).
197. Kim, C. et al. Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease. J. Neuroinflammation 12, 236 (2015).
198. Burre, J. et al. Properties of native brain α-synuclein. Nature 498, E4-E6, discussion E6-7 (2013).
199. Theillet, F.X. et al. Structural disorder of monomeric α-synuclein persists in mammalian cells. Nature 530, 45-50 (2016).
200. Gould, N. et al. Evidence of native α-synuclein conformers in the human brain. J. Biol. Chem. 289, 7929-7934 (2014).
201. Wang, W. et al. A soluble α-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. USA 108, 17797-17802 (2011).
202. Bartels, T., Choi, J.G. & Selkoe, D.J. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-110 (2011).
203. Dettmer, U., Newman, A.J., von Saucken, V.E., Bartels, T. & Selkoe, D. KTKEGV repeat motifs are key mediators of normal α-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity. Proc. Natl. Acad. Sci. USA 112, 9596-9601 (2015).
204. Sharon, R. et al. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595 (2003).
205. Ferreon, A.C., Gambin, Y., Lemke, E.A. & Deniz, A.A. Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc. Natl. Acad. Sci. USA 106, 5645-5650 (2009).
206. Buell, A.K. et al. Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proc. Natl. Acad. Sci. USA 111, 7671-7676 (2014).
207. Galvagnion, C. et al. Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol. 11, 229-234 (2015).
208. Cremades, N. et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149, 1048-1059 (2012).
209. Conway, K.A. et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571-576 (2000).
210. Winner, B. et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. USA 108, 4194-4199 (2011).
211. Pieri, L., Madiona, K., Bousset, L. & Melki, R. Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys. J. 102, 2894-2905 (2012).
212. Fares, M.B. et al. Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease. Proc. Natl. Acad. Sci. USA 113, E912-E921 (2016).
213. Luk, K.C. et al. Molecular and biological compatibility with host alpha-synuclein influences fibril pathogenicity. Cell Rep. 16, 3373-3387 (2016).
214. Prusiner, S.B. et al. Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc. Natl. Acad. Sci. USA 112, E5308-E5317 (2015).
215. Woerman, A.L. et al. Propagation of prions causing synucleinopathies in cultured cells. Proc. Natl. Acad. Sci. USA 112, E4949-E4958 (2015).